Short answer
ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement). ATM offering up to $100M in common stock via Cantor Fitzgerald, filed March 10, 2026 under existing S-3 shelf registration.
ROCKET PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM offering up to $100M in common stock via Cantor Fitzgerald, filed March 10, 2026 under existing S-3 shelf registration
- Sales agent commission up to 3.0% of gross proceeds: maximum dilution cost ~$3M if fully drawn
- Company controls timing, volume, and minimum price floor; no obligation to sell any shares
- Signals potential near-term cash needs for pipeline development or operational runway extension
- Investors should monitor actual share sales via Form 424B3 prospectus supplements for real-time dilution tracking
Item 1.02 · Termination of a Material Definitive Agreement
- Rocket Pharma terminated its prior ATM agreement with Cowen and Company (TD Securities affiliate), originally dated Feb 28, 2022
- Termination triggered by entry into a new Sales Agreement, signaling a change in ATM program counterparty or structure
- Prior ATM allowed open-ended at-the-market common stock sales: termination removes that existing dilution channel, replaced by new one
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ROCKET PHARMACEUTICALS, INC. 8-K filings
Get the next RCKT 8-K as it lands
Follow RCKT for push alerts, or ask the research agent what this filing means.